Home ProductsAPI Powder

Febuxostat API Powder / Cas No 144060-53-7 High Purity Pharmaceutical Powders

Febuxostat API Powder / Cas No 144060-53-7 High Purity Pharmaceutical Powders

    • Febuxostat API Powder / Cas No 144060-53-7 High Purity Pharmaceutical Powders
    • Febuxostat API Powder / Cas No 144060-53-7 High Purity Pharmaceutical Powders
  • Febuxostat API Powder / Cas No 144060-53-7 High Purity Pharmaceutical Powders

    Product Details:

    Place of Origin: China
    Brand Name: Leji
    Model Number: Febuxostat

    Payment & Shipping Terms:

    Minimum Order Quantity: Negotiation
    Price: Negotiation
    Packaging Details: Aluminum Foil Bag, barrel, or drum.
    Delivery Time: 7-15 working days
    Payment Terms: T/T, western union, moneygram
    Supply Ability: 5 - 25 metric ton per month
    Contact Now
    Detailed Product Description
    Other Names: Febuxostat Appearance: White Crystal Powder
    Application: Pharmaceuticals API Cas No.: 144060-53-7
    Mf: C16H16N2O3S Type: Anti-Allergic Agents
    Density: 1.31g/cm3 Water Solubility: 0.2 G/L
    Melting Point: 238-239°(dec.) Boiling Point: 536.6±60.0 °C(Predicted)
    Flash Point: 278.3°C Vapour Pressure: 2.41E-12mmHg At 25°C
    Storage Condition: -20°C Refractive Index: 1.605
    Package: 25kg/carton Drum Shelf Life: 2 Years
    High Light:

    pharmaceutical raw materials

    ,

    intermediate pharma

    Febuxostat API Cas No. 144060-53-7 High Purity pharmaceutical Powder

    Febuxostat API Powder 

     

    Description

      Febuxostat is a new generation of xanthine oxidase inhibitor developed by Japanese company. It is used in the treatment of gout. Its structure is totally different from that of xanthine oxidase inhibitor developed 40 years ago. It is a new and efficient selective inhibitor of non purine xanthine oxidase. Xanthine oxidase is the key enzyme to promote the production of uric acid. Febuxostat can reduce the level of chemical Book uric acid in the blood of gout patients with hyperuricemia. The clinical research shows that the product is safe and effective. The product is metabolized through the liver and does not depend on renal excretion. Therefore, it is not necessary to reduce the dosage of febuxostat in patients with moderate to severe hepatorenal insufficiency. The dosage is 40 mg or 80 mg once a day. It is not recommended to treat gout patients without hyperuricemia. In February 2009, the U.S. Food and Drug Administration (FDA) approved febuxostat for the long-term treatment of gout hyperuricemia.

     

     

     

    Product Parameters

     

    CAS No. 144060-53-7
    Molecular Formula C16H16N2O3S
    LogP 3.72318
    PSA 111.450
    Flash point 278.3°C
    Melting point 238-239°(dec.)
    Boiling point 536.6±60.0 °C(Predicted)
    Density

    1.31g/cm3

    Shelf life 2 Years

     

     

    Function

      

     

       Gout is a group of heterogeneous diseases, which is caused by heredity or acquisitiveness. Due to the excessive production of uric acid in the body and the decrease of renal clearance, the accumulation of uric acid in the body leads to the deposition of urate crystals in joints and organs. Therefore, gout is usually treated by promoting the excretion of uric acid and inhibiting the production of uric acid, and taking appropriate measures to improve the related symptoms.
       The production of uric acid in vivo is related to purine metabolism. In the last step of purine metabolism, hypoxanthine generates xanthine under the action of xanthine oxidoreductase (XOR), and then further generates uric acid. Inhibiting the activity of XOR can effectively reduce the production of uric acid. Febuxostat is a new generation of non purine selective xanthine oxidase inhibitor. It can reduce the synthesis of uric acid in vivo and the concentration of uric acid through highly selective action on the oxidase, so as to effectively treat ventilation diseases.
      

    Application

     

       

       In the past 30 years, allopurinol is the only drug used to inhibit the production of uric acid in clinic. It has been widely used as the gold treatment drug for gout, and has made great achievements in the treatment of gout. Compared with allopurine, febuxostat has obvious advantages:
         (1) Allopurinol can only inhibit XOR, while febuxostat can significantly inhibit XOR, so its effect of reducing uric acid is more powerful and lasting;
         (2) Since allopurinol is a purine analogue, it inevitably affects the activity of other enzymes involved in purine and pyridine metabolism. Therefore, in the treatment of allopurinol, it is necessary to repeat high dose administration to maintain high drug level. It also leads to serious and even fatal adverse reactions caused by drug accumulation. Febuxostat is a non purine XOR inhibitor, so it has better safety.

     

    FAQ

     

    Q1: How long is your delivery time?

     

    A: Prompt shipment after receipt of order confirmation for regular products. Generally it is 1-5 days if the goods are in stock. or it is 5-15 days if the goods are not in stock, it is according to quantity.

     
    Q2: How much for the freight?
     
    A: It depends on your area, we will use DHL, FedEx and EMS bulk service, it had discount as normal express service.
     
    Q3: How can i release the payment to you?
     
    A: We can receive your payment by T/T, moneygram or Western union which is recommended.

    Contact Details
    Wuxi Leji Biological Technology Co., Ltd

    Contact Person: Max

    Send your inquiry directly to us (0 / 3000)